What characterizes an ideal, sustainable biosimilar market that improves patient access to safe and high-quality biological therapies and meets the interests of all stakeholders? IQVIA’s white paper “The Impact of Biosimilar Competition in Europe” explores this and other questions. While the topic of interchangeability plays a crucial role according to IQVIA, a balance of access, regulation, competition and incentive systems is most promising for a sustainable biosimilar market.
Read more in the IQVIA white paper:
